Skip to main content

Table 2 Standardized incidence ratios (SIRs) of cancers in patients with RPF

From: Association of retroperitoneal fibrosis with malignancy and its outcomes

  Observed Expected SIR [95% CI] Corrected p
Overall SIR 38 17.1 2.2 [1.6, 3.1] <0.001
 Male 26 13.7 1.9 [1.2, 2.8] <0.001
 Female 12 3.4 3.5 [1.8, 6.2] <0.001
Age-specific SIR
 30–39 1 0.23 4.3 [0.1, 23.7] 0.419
 40–49 4 0.91 4.4 [1.2, 11.2] 0.028
 50–59 8 2.83 2.8 [1.2, 5.6] 0.017
 60–69 11 6.58 1.7 [0.8, 3.0] 0.143
 70–79 12 5.48 2.2 [1.1, 3.8] 0.022
 ≥ 80 2 1.00 2.0 [0.2, 7.2] 0.529
Interval-specific SIR, yearsa
 −20 ~ −5 5 6.47 0.77 [0.3, 1.8] 0.747
 −5 ~ −3 0 1.95 0
 −3 ~ −1 4 2.26 1.8 [0.5, 4.6] 0.365
 −1 ~ +1 22 2.22 9.9 [6.2, 15.0] <0.001
 +1 ~ +3 2 1.33 1.5 [0.2, 5.4] 0.771
 +3 ~ +5 3 0.83 3.6 [0.8, 10.6] 0.102
 +5 ~ 2 2.02 1.0 [0.1, 3.6] 1.000
Cancer type-specific SIR
 Lung 4 2.7 1.5 [0.4, 3.9] 0.555
 Stomach 6 3.3 1.8 [0.7, 4.0] 0.228
 GIST 1 0.06 16.4 [0.4, 91.2] 0.119
 Colon 3 1.26 2.4 [0.5, 7.0] 0.268
 Rectum 1 1.05 1.0 [0.0, 5.3] 1.000
 Pancreas 2 0.49 4.1 [1.0, 14.8] 0.174
 Kidney 2 0.31 6.4 [0.8, 23.2] 0.079
 Renal pelvis 3 0.04 74.4 [15.4, 217.5] <0.001
 GB and biliary tract 1 0.53 1.9 [0.1, 10.6] 0.818
 Bladder 1 0.46 2.2 [0.1, 12.1] 0.739
 Prostate 1 1.04 1.0 [0.0, 5.4] 1.000
 MM 2 0.11 19.0 [2.3, 68.5] 0.010
 NHL 1 0.29 3.5 [0.1, 19.4] 0.500
 Connective and soft tissue 1 0.06 15.5 [0.4, 86.2] 0.125
 MDS 1 0.06 16.8 [0.4, 93.5] 0.116
 Thyroid 2 0.74 2.7 [0.3, 9.8] 0.339
 Breast 1 0.41 2.4 [0.1, 13.4] 0.679
 Cervix uteri 1 0.18 5.5 [0.1, 30.9] 0.330
 Larynx 1 0.19 5.3 [0.1, 29.7] 0.342
 Skinb 1 0.25 3.9 [0.1, 21.9] 0.449
 Unknown primary 2 0.20 9.8 [1.2, 35.4] 0.037
  1. Data are expressed as SIR (95% CI). RPF retroperitoneal fibrosis; GIST gastrointestinal stromal tumor; GB gall bladder; MM multiple myeloma; NHL non-Hodgkin lymphoma; MDS myelodysplastic syndrome. aThe interval was calculated using the data of RPF diagnosis as a reference. bGiven that the Korean National Cancer Registry data were available between 1999 and 2016, the 1999 cancer incidence was used to extrapolate the expected cancer occurrence for a skin cancer that was diagnosed in 1996